Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)

Cancer incidence has been increasing worldwide in the last few decades. Solid tumors are hard to treat, primarily due to drug resistance as well as to the struggle in delivering the drugs specifically to the tumor. Various therapeutic approaches for treating solid tumors have been exploited. A very...

Full description

Saved in:
Bibliographic Details
Main Author: Farhat, Stephanie Roy (author)
Format: masterThesis
Published: 2016
Subjects:
Online Access:http://hdl.handle.net/10725/4899
https://doi.org/10.26756/th.2016.25
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513464908644352
author Farhat, Stephanie Roy
author_facet Farhat, Stephanie Roy
author_role author
dc.creator.none.fl_str_mv Farhat, Stephanie Roy
dc.date.none.fl_str_mv 2016-12-08T10:05:43Z
2016-12-08T10:05:43Z
2016
2016-12-08
2016-04-22
dc.identifier.none.fl_str_mv http://hdl.handle.net/10725/4899
https://doi.org/10.26756/th.2016.25
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php
dc.language.none.fl_str_mv en
dc.publisher.none.fl_str_mv Lebanese American University
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv Ruthenium compounds
Cancer -- Treatment -- Research
Dissertations, Academic
Lebanese American University -- Dissertations
dc.title.none.fl_str_mv Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
dc.type.none.fl_str_mv Thesis
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/masterThesis
description Cancer incidence has been increasing worldwide in the last few decades. Solid tumors are hard to treat, primarily due to drug resistance as well as to the struggle in delivering the drugs specifically to the tumor. Various therapeutic approaches for treating solid tumors have been exploited. A very promising approach has been the use of Ruthenium-based complexes conjugated to different ligands that are characterized by having a photochemical potential rendering them only active after exposure to light, which can be ultimately specifically delivered to the site of tumor. This study aims to find the most efficient Ru-based compounds on a set of 6 cell lines from different solid tumors. Different ruthenium precursors (bis-bidentate), final complexes (tris-bidentate) and free phenanthroline- or bipyridine-derived ligands were tested. The bis-bidentate complexes tested were four: Ru-I: [Ru(II)(1,10-phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2Cl2]; Ru-III: [Ru(II)(4,7-diphenyl-1,10-phenanthroline-disulfonate)2Na2]2+ and Ru-IV: [Ru(II)(2,2'-bipyridine)2Cl2], along with their corresponding free ligands L-I, L-II, L-III and L-IV, respectively. Ru-II showed significant potency on most of the cell lines tested (5 out of 6), as well as Ru-I on two of them while the others were inert. As for the free ligands, L-II presented major cytotoxic effect on five out of six cell lines, L-I on two cell lines, L-IV on one cell line only. The addition of diphenyl groups to the phenanthroline of L-I rendered its structure bulkier and more hydrophobic (L-II), and showed an increase in its potent activity, same result when it was bound to the metal. Therefore, a structure activity relationship was established between precursors and their free ligands. However, when adding sulfonate groups to the diphenylphenanthroline structures, the cytotoxic effect is inhibited in the free ligand and its precursor, L-III and Ru-III respectively, thus suggesting a possible DNA intercalation mechanism of these compounds. On the other hand, neither bipyridine nor its corresponding precursor L-IV and Ru-IV, bipyridine and its corresponding precursor respectively, shown no cytotoxic activity. In addition, four final compounds were synthesized to study the photochemical potential of our metal-based complexes. There structure bear combinations of L-II and L-III yielding the tris-bidentate compounds, Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3, having different net charges ranging between +2 and -4, and their effect was studied in the dark and after exposure to blue light. Activity was detected only in Ru-II3 against all the tested cell lines in the dark, Ru-II2-III in three cell lines while the others showed no effect. When exposed to blue light against the astrocytoma cell line all four compounds showed high levels of potency, including Ru-II-III2 and Ru-III3 that were biologically inert in the dark. It is hypothesized that these final compounds’ cytotoxic action is due to the generation of Reactive Oxygen Species (ROS), causing DNA damage, oxidation of amino acids and enzyme co-factors, as well as lipid peroxidation, thus leading to cell death. The ultimate goal is to base future selective anticancer treatments using Ru-based compounds. The mechanisms by which Ru-based compounds work is still being explored, and other ligands and combination of ligands are also being tested to find the most selective, and potent complex.
eu_rights_str_mv openAccess
format masterThesis
id LAURepo_e0818ef284acd8c87c0cfc0f8be43d8f
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/4899
publishDate 2016
publisher.none.fl_str_mv Lebanese American University
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)Farhat, Stephanie RoyRuthenium compoundsCancer -- Treatment -- ResearchDissertations, AcademicLebanese American University -- DissertationsCancer incidence has been increasing worldwide in the last few decades. Solid tumors are hard to treat, primarily due to drug resistance as well as to the struggle in delivering the drugs specifically to the tumor. Various therapeutic approaches for treating solid tumors have been exploited. A very promising approach has been the use of Ruthenium-based complexes conjugated to different ligands that are characterized by having a photochemical potential rendering them only active after exposure to light, which can be ultimately specifically delivered to the site of tumor. This study aims to find the most efficient Ru-based compounds on a set of 6 cell lines from different solid tumors. Different ruthenium precursors (bis-bidentate), final complexes (tris-bidentate) and free phenanthroline- or bipyridine-derived ligands were tested. The bis-bidentate complexes tested were four: Ru-I: [Ru(II)(1,10-phenanthroline)2Cl2]; Ru-II: [Ru(II)(4,7-diphenyl-1,10-phenanthroline)2Cl2]; Ru-III: [Ru(II)(4,7-diphenyl-1,10-phenanthroline-disulfonate)2Na2]2+ and Ru-IV: [Ru(II)(2,2'-bipyridine)2Cl2], along with their corresponding free ligands L-I, L-II, L-III and L-IV, respectively. Ru-II showed significant potency on most of the cell lines tested (5 out of 6), as well as Ru-I on two of them while the others were inert. As for the free ligands, L-II presented major cytotoxic effect on five out of six cell lines, L-I on two cell lines, L-IV on one cell line only. The addition of diphenyl groups to the phenanthroline of L-I rendered its structure bulkier and more hydrophobic (L-II), and showed an increase in its potent activity, same result when it was bound to the metal. Therefore, a structure activity relationship was established between precursors and their free ligands. However, when adding sulfonate groups to the diphenylphenanthroline structures, the cytotoxic effect is inhibited in the free ligand and its precursor, L-III and Ru-III respectively, thus suggesting a possible DNA intercalation mechanism of these compounds. On the other hand, neither bipyridine nor its corresponding precursor L-IV and Ru-IV, bipyridine and its corresponding precursor respectively, shown no cytotoxic activity. In addition, four final compounds were synthesized to study the photochemical potential of our metal-based complexes. There structure bear combinations of L-II and L-III yielding the tris-bidentate compounds, Ru-II3, Ru-II2-III, Ru-II-III2 and Ru-III3, having different net charges ranging between +2 and -4, and their effect was studied in the dark and after exposure to blue light. Activity was detected only in Ru-II3 against all the tested cell lines in the dark, Ru-II2-III in three cell lines while the others showed no effect. When exposed to blue light against the astrocytoma cell line all four compounds showed high levels of potency, including Ru-II-III2 and Ru-III3 that were biologically inert in the dark. It is hypothesized that these final compounds’ cytotoxic action is due to the generation of Reactive Oxygen Species (ROS), causing DNA damage, oxidation of amino acids and enzyme co-factors, as well as lipid peroxidation, thus leading to cell death. The ultimate goal is to base future selective anticancer treatments using Ru-based compounds. The mechanisms by which Ru-based compounds work is still being explored, and other ligands and combination of ligands are also being tested to find the most selective, and potent complex.N/A1 hard copy: xvi, 94 leaves; col. ill.; 31 cm. available at RNL.Bibliography : leaves 53-65.Lebanese American University2016-12-08T10:05:43Z2016-12-08T10:05:43Z20162016-12-082016-04-22Thesisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10725/4899https://doi.org/10.26756/th.2016.25http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.phpeninfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/48992021-03-19T10:03:22Z
spellingShingle Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
Farhat, Stephanie Roy
Ruthenium compounds
Cancer -- Treatment -- Research
Dissertations, Academic
Lebanese American University -- Dissertations
status_str publishedVersion
title Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
title_full Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
title_fullStr Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
title_full_unstemmed Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
title_short Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
title_sort Targeting solid tumor cells with novel photosensitive ruthenium-based metal-organic compounds. (c2016)
topic Ruthenium compounds
Cancer -- Treatment -- Research
Dissertations, Academic
Lebanese American University -- Dissertations
url http://hdl.handle.net/10725/4899
https://doi.org/10.26756/th.2016.25
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php